financetom
Business
financetom
/
Business
/
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
Oct 3, 2024 10:07 AM

12:37 PM EDT, 10/03/2024 (MT Newswires) -- Eli Lilly ( LLY ) , CVS's (CVS) pharmacy unit and other drug companies and pharmacy benefit managers have been sued by Texas Attorney General Ken Paxton for allegedly inflating insulin prices, Paxton's office said Thursday.

Paxton accused the major insulin manufacturers of "artificially and willingly" raising prices and then paying pharmacy benefit managers "significant" amounts for preferred status in their standard offerings.

Insulin prices have been raised by as much as 1,000% over the last decade, Paxton said, in what he described as a "disturbing conspiracy."

"Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could," Paxton said.

The insulin pricing scheme violates the Texas Deceptive Trade Practices Act, he said.

Eli Lilly ( LLY ) and CVS did not immediately respond to MT Newswires' requests for comment.

Price: 887.49, Change: -3.58, Percent Change: -0.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amicus Therapeutics Says Japan Approval Received for Late-Onset Pompe Disease Treatment
Amicus Therapeutics Says Japan Approval Received for Late-Onset Pompe Disease Treatment
Jun 25, 2025
07:38 AM EDT, 06/25/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) said Wednesday it has received the approval of Japan's Ministry of Health, Labour and Welfare for the combination of Pombiliti and Opfolda to treat adult patients with late-onset Pompe disease. The approval was based on clinical data from a phase 3 trial, the company said, adding that the...
Genius Sports to be Added to Russell 3000 Index
Genius Sports to be Added to Russell 3000 Index
Jun 25, 2025
07:35 AM EDT, 06/25/2025 (MT Newswires) -- Genius Sports ( GENI ) said Wednesday that it will be added to the Russell 3000 Index on Monday as part of Russell indexes' annual reconstitution. Shares of Genius Sports ( GENI ) were up more than 2% in recent premarket activity. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths
Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths
Jun 25, 2025
07:35 AM EDT, 06/25/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) gene therapy, Elevidys, is being investigated by the US Food and Drug Administration following reports of two deaths after receiving the treatment, multiple media outlets reported Tuesday, citing the FDA. The investigation comes amid safety concerns after the company reported the second death earlier this month of a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved